Risk of Nerve Damage After Administration of Local Anesthesia

Conditions

• Inferior Alveolar Nerve Injuries

Eligibility Criteria

Sex

ALL

Age

18 Years - 55 Years

Healthy Volunteers

Accepted

Interventions

• 4% Articaine with 1:200,000 epinephrine — DRUG
  Inferior Alveolar Nerve Block with 4% articaine
• 2% lidocaine with 1:100,000 epinephrine — DRUG
  Inferior Alveolar Nerve Block with 2% lidocaine

Study Details

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.

Key Dates

Start date

Jan 1, 2024

Status verified

Jul 2024

Primary completion

Dec 31, 2024

Completion

Mar 31, 2025

Study Design

Enrollment

80 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Articaine
  Inferior Alveolar Nerve block using Articaine 4% with 1:200,000 epinephrine local anesthetic
• Active Comparator: Lidocaine
  Inferior Alveolar Nerve block using 2% lidocaine with 1:100,000 epinephrine local anesthetic

Primary Outcome Measure

Electromyograph [ Time Frame: 3 months ]

Central Contacts

• Pablo R Velazquez, Resident
  7546108595
  [email protected]
• Nelson A Rendon, Resident
  9548605748
  [email protected]

Locations (2)

Find similar trials in Akron, OH